About us

Imcyse is pioneering the development of a new class of active, specific immunotherapeutics: ImotopesTM. Imcyse’s new technology platform is based on the discovery of modified synthetic peptides to block the immune processes causing immune-mediated diseases. Imcyse’s ImotopesTM  offer the possibility to cure severe chronic diseases for which there is no satisfactory therapeutic alternative. The technology can also prevent the immunogenic responses that weaken the efficiency of chronic therapies. 

Our vision is to become a major player in active specific immunotherapy for the curative treatment of autoimmune and allergic diseases.


Latest news

Imcyse announces a research collaboration with Pfizer Inc. in rheumatoid arthritis (RA)

Imcyse SA announces that it has entered into a research collaboration with Pfizer Inc. (NYSE: PFE) for development of an ImotopeTM, a specific modified peptide, targeting rheumatoid arthritis (RA). Under the terms of the agreement, Pfizer will provide an undisclosed amount to fund the research activities, and Pfizer has an exclusive option to negotiate a license agreement for a limited period following the research activities. Additionally, Pfizer will perform preclinical evaluation of another of Imcyse’s Imotopes targeting multiple sclerosis (MS) to better understand the mode of action of Imcyse's Imotope technology platform. Imcyse will have access to select technology platforms at Pfizer as well as all research results related to this collaboration.